Androgenetic Alopecia - Male Pattern Baldness

What is it?

Male pattern baldness, or androgenetic alopecia in men, is a hereditary condition characterized by progressive hair loss following a predictable pattern of frontal and vertex (crown) thinning. This genetically programmed sensitivity to dihydrotestosterone (DHT) causes hair follicles to gradually miniaturize, producing progressively finer hairs until they cease producing hair altogether.

Who is affected?

Male pattern baldness is the most common cause of hair loss in men, affecting the majority of men to some degree during their lifetime.

• Prevalence: Affects 3 in 10 men (30%) by age 30; 1 in 2 men (50%) by age 50; 4 in 5 men (80%) by age 70-80
• Age demographics: Can begin as early as late teens; most commonly first noticed in the 20s-30s; progression continues throughout life without treatment
• Ethnic variations: Most prevalent in Caucasian men; followed by Asian populations; least common in African American men who also tend to have later onset
• Risk factors: Strong family history (either maternal or paternal lineage); early onset predicts more severe progression; associated with coronary heart disease, prostate enlargement, and metabolic syndrome

What causes it?

The condition results from genetic predisposition and hormonal factors:

• Primary mechanisms: Genetically susceptible hair follicles respond to dihydrotestosterone (DHT); enzyme 5-alpha-reductase converts testosterone to DHT in scalp; DHT binds to androgen receptors causing follicular miniaturization; shortened anagen (growth) phase from 3-6 years to weeks or months
• Genetic inheritance: Polygenic trait involving multiple genes; androgen receptor (AR) gene on X chromosome plays major role; can be inherited from either parent despite common belief of maternal inheritance only; earlier onset typically indicates stronger genetic predisposition
• Hormonal factors: Requires presence of androgens - castrated men before puberty don't develop baldness; DHT levels may be normal but follicle sensitivity is increased; 5-alpha-reductase activity higher in balding areas
• Cellular changes: Progressive miniaturization of follicles; decreased follicle depth; reduced hair shaft diameter; eventual transformation to vellus follicles that produce only fine, short hairs

What are the clinical features?

Male pattern baldness follows a characteristic and predictable progression pattern:

• Hamilton-Norwood classification: Stage I-II - minimal frontal recession, mature hairline; Stage III - deepening temporal recession creating "M-shaped" hairline; Stage III vertex - crown thinning begins; Stage IV-V - frontal and vertex loss with narrowing bridge between; Stage VI-VII - extensive loss leaving only horseshoe pattern of remaining hair
• Clinical features: Bitemporal recession typically appears first (receding hairline); vertex (crown) thinning develops subsequently; hair becomes progressively finer and shorter before ceasing growth; temporal and occipital areas remain unaffected (donor areas for transplantation)
• Hair changes: Affected hairs show progressive miniaturization; terminal hairs convert to vellus-like hairs; decreased hair density becomes noticeable; scalp becomes increasingly visible
• Disease progression: Gradual onset over years to decades; rate of progression varies - some lose most hair within 5 years, others over 15-25 years; without treatment, progression is continuous

How is it diagnosed?

Diagnosis is typically straightforward based on pattern and history:

• Clinical assessment: Recognition of characteristic Hamilton-Norwood pattern; family history of male pattern baldness; gradual onset and progression over years; dermoscopy shows hair diameter diversity (>20% variation) and miniaturized hairs
• Laboratory tests: Usually unnecessary for typical cases; consider thyroid function if rapid or unusual pattern; iron studies if concurrent diffuse thinning; hormonal evaluation rarely needed unless signs of hormonal abnormality
• Differential diagnosis: Must distinguish from alopecia areata (patchy loss with exclamation mark hairs); telogen effluvium (diffuse shedding with positive pull test); scarring alopecias (permanent follicle destruction)
• Scalp biopsy: Rarely required but shows miniaturized follicles with normal total follicle count

What treatment options are available?

Treatment focuses on slowing progression and promoting regrowth, with best results from early intervention:

• Oral finasteride (first-line treatment): 1 mg daily tablet; FDA-approved since 1997; 5-alpha-reductase type 2 inhibitor reducing DHT by 70%; slows hair loss in 90% and promotes regrowth in 65% at 2 years; most effective for crown, moderate for frontal; results visible after 3-6 months, peak at 1-2 years; must continue indefinitely - hair loss resumes within 12 months of stopping
• Topical minoxidil: 5% solution or foam applied twice daily to affected areas; stimulates follicles and prolongs growth phase; effective in 60-70% of users; works synergistically with finasteride; initial shedding common at 2-8 weeks; must continue indefinitely
• Oral dutasteride (off-label): 0.5 mg daily; inhibits both type 1 and 2 5-alpha-reductase; reduces DHT by 90% (vs 70% with finasteride); potentially more effective but longer half-life
• Emerging treatments: Topical finasteride - reduced systemic absorption; oral minoxidil 2.5-5 mg daily showing promise; platelet-rich plasma (PRP) injections monthly; low-level laser therapy devices
• Hair transplantation: Follicular unit extraction (FUE) or transplantation (FUT); permanent solution using DHT-resistant donor hair; best combined with medical therapy to preserve existing hair; requires adequate donor area
• Expected outcomes: Earlier treatment yields better results; combination therapy more effective than monotherapy; maintenance of existing hair often more achievable than significant regrowth; continuous treatment required - cessation leads to catch-up hair loss

Key points for patients

• Male pattern baldness affects the majority of men and is a normal genetic trait, not a disease
• Early treatment is crucial - it's easier to maintain existing hair than regrow lost hair
• FDA-approved medications (finasteride and minoxidil) are effective but require indefinite use
• When to seek medical attention: Sudden or patchy hair loss (may indicate different condition); rapid progression in young age; considering treatment options; concerns about medication side effects
• Important considerations: Finasteride may cause sexual side effects in 2-4% of users, usually reversible; both medications require 3-6 months to show results - patience needed; hair transplantation offers permanent results but is costly; psychological impact should not be underestimated - counseling available